Second-line CML drug evokes faster response, fewer side effects, pivotal study finds
Saturday, June 5, 2010 - 10:10
in Health & Medicine
Dasatanib, a medication currently approved as treatment for drug-resistant chronic myeloid leukaemia (CML), provided patients with quicker, better responses as a first therapy than the existing front-line drug, according to researchers at The University of Texas MD Anderson Cancer Centre...